[an error occurred while processing this directive]|[an error occurred while processing this directive]
基于调强放疗的鼻咽癌临床分型研究
张冉,吴君心,徐鹭英,林少俊,杨凌,陈传本,潘建基
350014 福州,福建医科大学省立临床医学院 福建省肿瘤医院放疗科
Study on clinical typing of nasopharyngeal carcinoma in patients treated by intensity-modulated radiotherapy
ZHANG Ran,WU Jun-xin, XU Lu-ying, LIN Shao-jun, YANG Ling, CHEN Chuan-ben, PAN Jian-ji．
Department of Radiation Oncology,Fujian Provincial Cancer Hospital;School of Clinical Medicine, Fujian Provincial Hospital, Fujian Medical University;Fuzhou 350014,China
Objective To investigate the clinical typing of nasopharyngeal carcinoma in patients treated by intensity-modulated radiation therapy (IMRT). Methods A retrospective analysis was performed on 333 patients with nasopharyngeal carcinoma who were initially treated in our hospital from 2003 to 2006;they had no distant metastasis and received IMRT. These patients were divided into 4 clinical types according to their prognosis:type Ⅰ(without local-regional recurrence and without distant metastasis), type Ⅱ(with local-regional recurrence and without distant metastasis), type Ⅲ(without local-regional recurrence and with distant metastasis), and type Ⅳ(with local-regional recurrence and with distant metastasis). Results Of all the patients, 70.0%(233) were of type Ⅰ,12.9%(43) of type Ⅱ, 16.5%(55) of type Ⅲ, and 0.6%(2) of type Ⅳ. Of 57 patients with stage Ⅰ—Ⅱ nasopharyngeal carcinoma, 86%(49) were of type Ⅰ, 11%(6) of type Ⅱ, 4%(2) of type Ⅲ, and 0%(0) of type Ⅳ, and of 276 patients with stage Ⅲ—Ⅳ nasopharyngeal carcinoma, 66.7%(184) were of type Ⅰ, 13.4%(37) of type Ⅱ, 19.2%(53) of type Ⅲ, and 0.7%(2) of type Ⅳ, with significant differences between the two patient groups (P=0.007). Of the 69 patients who received IMRT alone, 80%(55) were of type Ⅰ, 12%(8) of type Ⅱ, 9%(6) of type Ⅲ, and 0%(0) of type Ⅳ;of the 218 patients who received IMRT combined with neoadjuvant plus concurrent chemotherapy, 68.8%(150) were of type Ⅰ,13.8%(30) of type Ⅱ, 16.5%(36) of type Ⅲ, and 0.9%(2) of type Ⅳ;of the 46 patients who received IMRT combined with neoadjuvant plus adjuvant chemotherapy, 61%(28) were of type Ⅰ, 11%(5) of type Ⅱ, 28%(13) of type Ⅲ, and 0%(0) of type Ⅳ. Conclusions In patients with early and advanced nasopharyngeal carcinoma, type Ⅰ is the most common, and type Ⅳ is the least common;type Ⅱ is more frequent than type Ⅲ in early patients, while type Ⅲ is more frequent than type Ⅱ in advanced patients. The percentage of type Ⅰ patients increases, while that of type Ⅱ—Ⅳ patients decreases, as compared with the data of those treated by conventional radiotherapy.
ZHANG Ran,WU Jun-xin,XU Lu-ying et al. Study on clinical typing of nasopharyngeal carcinoma in patients treated by intensity-modulated radiotherapy[J]. Chinese Journal of Radiation Oncology, 2013, 22(3): 217-219.
[1] 徐国镇,唐平章,罗京伟.加强以放疗为主的鼻咽癌综合治疗研究.中华耳鼻咽喉头颈外科杂志,2012,47:177-179. [2] 马骏,麦海强,莫浩元,等.鼻咽癌放疗失败原因分析.癌症,2000,19:1016-1018. [3] 易俊林,高黎,黄晓东,等.鼻咽癌放疗的失败模式.中华放射肿瘤学杂志,2004,13:145-148. [4] 谢志光,李振权．鼻咽癌的自然发展及晚期病例的临床分型．天津医药杂志肿瘤学附刊,1963,1:129. [5] 李振权.鼻咽癌临床表现和诊断//李振权,潘启超,陈剑经．鼻咽癌临床与实验研究．广州:广东科技出版社,1983:154-158. [6] Li ZQ, Xia YF, Liu Q,et al. Radiotherapy-related typing in 842 patients in canton with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys,2006,66:1011-1016. [7] 李志强,夏云飞,柳青,等.鼻咽癌放疗分型的临床研究.中华医学杂志,2006,86:3272-3276. [8] Lin S, Pan J, Han L,et al. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy:report on the 3-year outcome of a prospective series. Int J Radiat Oncol Biol Phys,2009,75:1071-1078. [9] 赖淑贞.调强适形放疗对比常规二维放疗对鼻咽癌疗效的影响.广州:中山大学,2007. [10] 赵充,卢丽霞,韩非,等．调强适形放疗对局部晚期鼻咽癌的临床疗效.癌症,2004,23:1532-1537. [11] Lin S, Tham IW, Pan J,et al. Combined high-dose radiation therapy and systemic chemotherapy improves survival in patients with newly diagnosed metastatic nasopharyngeal cancer. Am J Clin Oncol,2012,35:474-479.
2013, Vol. 22 
